AA
IMMU

ALPS Advisors’s Immunomedics Inc IMMU Stock Holding History

ALPS Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-373,785
Closed -$5.04M – 843
2020
Q1 		$5.04M Sell
373,785
-41,734
-10% -$702K 0.08% 143
2019
Q4 		$8.79M Buy
415,519
+32,746
+9% +$578K 0.07% 122
2019
Q3 		$5.08M Sell
382,773
-16,627
-4% -$244K 0.04% 141
2019
Q2 		$5.54M Sell
399,400
-60,556
-13% -$911K 0.04% 149
2019
Q1 		$8.84M Buy
459,956
+37,022
+9% +$597K 0.06% 128
2018
Q4 		$6.04M Buy
422,934
+103,612
+32% +$2.06M 0.05% 140
2018
Q3 		$6.65M Buy
319,322
+77,451
+32% +$1.83M 0.04% 140
2018
Q2 		$5.72M Buy
241,871
+19,518
+9% +$392K 0.04% 162
2018
Q1 		$3.25M Buy
222,353
+53,897
+32% +$881K 0.03% 174
2017
Q4 		$2.72M Buy
+168,456
New +$1.99M 0.02% 172

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ALPS Advisors's IMMU Position: Q2 2020 in Review

ALPS Advisors sold out of Immunomedics Inc (IMMU) in Q2 2020, closing a stake of 373,785 shares — an estimated $5.04M sold.

ALPS Advisors first reported a position in IMMU in Q4 2017 and held it in 10 quarters. The position peaked at $8.84M in Q1 2019. 313 funds tracked by Wall St. Rank hold IMMU as of Q2 2020.

  • ALPS Advisors reported no remaining Immunomedics Inc position as of Q2 2020 after selling out during the quarter.
  • ALPS Advisors sold 373,785 Immunomedics Inc shares in Q2 2020, an estimated $5.04M.
  • ALPS Advisors first reported a position in Immunomedics Inc in Q4 2017 and held it in 10 quarters.
  • ALPS Advisors's Immunomedics Inc position peaked at $8.84M in Q1 2019.
  • 313 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2020.

Based on ALPS Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.